Skip to main content

Liptruzet FDA Approval History

FDA Approved: Yes (Discontinued) (First approved May 3, 2013)
Brand name: Liptruzet
Generic name: atorvastatin and ezetimibe
Dosage form: Tablets
Company: Merck
Treatment for: High Cholesterol, Familial Heterozygous

Marketing Status: Discontinued

Liptruzet (atorvastatin and ezetimibe) is a statin (HMG-CoA reductase inhibitor) and cholesterol absorption inhibitor combination indicated for the treatment of hyperlipidemia.

Development timeline for Liptruzet

DateArticle
May  3, 2013Approval FDA Approves Merck’s Liptruzet (ezetimibe and atorvastatin), a New Product That Can Help Lower LDL Cholesterol
Jan  3, 2013Merck Announces FDA Acknowledgement of Resubmission of New Drug Application for Ezetimibe/Atorvastatin Tablets

See also

Liptruzet (atorvastatin and ezetimibe) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer